AI-generated summary
The authors used a computer model built from 24-month LIGHTSITE III trial data and natural history data to estimate the cost-effectiveness of photobiomodulation for intermediate dry age-related macular degeneration from a US payer perspective. They report a base-case cost per quality-adjusted life-year below common US willingness-to-pay thresholds, driven mainly by a reported reduction in incident geographic atrophy. The findings depend on modeled assumptions and utility mappings and the authors note they require independent replication.
- Who or what was studied
- Modeled cohort of adults with bilateral intermediate dry age-related macular degeneration and best-corrected visual acuity 20/32 to 20/100, consistent with LIGHTSITE III eligibility
- Limits stated in the abstract
- Results rely on a modeled cohort with utilities mapped from visual acuity and VFQ-25 data rather than prospective EQ-5D collection, and the geographic atrophy reduction needs independent replication.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Age-related macular degeneration, Replication. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.